Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELCHIOR, JAMES RYLAND | 1 | 61.0% | +44.6% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| PATTERSON, SARAH COOPER | 1 | 58.6% | +56.4% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 73.2% | +31.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | EDGINGTONGIORDANO, FRANCESCA | 66d overdue |
| 18451025 | NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF | MELCHIOR, JAMES RYLAND | 17d overdue |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | PATTERSON, SARAH COOPER | 7d |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1644 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18451025 | NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF | MELCHIOR, JAMES RYLAND | 1644 | Other | Non-Final OA | 17d overdue | Pending | Aug 16, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | CESARE, JOSEPH DAVID | 1675 | Other | Non-Final OA | 5d | Pending | Aug 07, 2023 |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | PATTERSON, SARAH COOPER | 1675 | Other | Non-Final OA | 7d | Pending | Dec 20, 2022 |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | EDGINGTONGIORDANO, FRANCESCA | 1643 | Other | Final Rejection | 66d overdue | Pending | Jun 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial